INCR
NASDAQ · Pharmaceuticals
Intercure Ltd
$5.31
+0.00 (+0.00%)
Financial Highlights (FY 2026)
Revenue
951.02M
Net Income
-121,357,062
Gross Margin
14.9%
Profit Margin
-28.4%
Rev Growth
+2.8%
D/E Ratio
0.46
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 14.9% | 14.9% | 42.1% | 42.1% |
| Operating Margin | -28.1% | -25.3% | 25.4% | 23.5% |
| Profit Margin | -28.4% | -27.0% | 18.6% | 18.8% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 951.02M | 924.85M | 56.95M | 44.24M |
| Gross Profit | 141.70M | 137.80M | 23.96M | 18.61M |
| Operating Income | -267,617,530 | -234,227,148 | 14.46M | 10.41M |
| Net Income | -121,357,062 | -106,215,458 | 10.61M | 8.30M |
| Gross Margin | 14.9% | 14.9% | 42.1% | 42.1% |
| Operating Margin | -28.1% | -25.3% | 25.4% | 23.5% |
| Profit Margin | -28.4% | -27.0% | 18.6% | 18.8% |
| Rev Growth | +2.8% | +2.8% | -4.9% | +12.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 30.34M | 30.34M | 21.12M | 16.64M |
| Total Equity | 65.73M | 65.73M | 85.08M | 101.00M |
| D/E Ratio | 0.46 | 0.46 | 0.25 | 0.16 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -64,808,024 | -59,873,210 | 17.54M | 14.43M |
| Free Cash Flow | — | — | 14.62M | 7.88M |